Human papillomavirus and head and neck squamous cell carcinomas in the South-East of France: prevalence, viral expression, and prognostic implications

Abstract

HPV DNA tested positive in 11.5% of biopsy samples. The HPV prevalence was higher in OSCCs (91.3 vs 27.3, p < 0.0001) and in patients not consuming tobacco (65.2% vs 95.4%, p < 0.0001). The estimated 3-year overall survival rates were 67.0% for HPV-infected patients versus 39.9% for non-infected patients. The high-risk HPV 16 was the most common type detected (65.2%). In 12 of 18 patients exhibiting DNA of high-risk HPV in their tumor tissue, the same viral genome was also present in normal tissue. E6 and E7 expression was found in 9 of 14 tumoral biopsies tested for these markers.

Incidence trends for potentially human papillomavirus‐related and ‐unrelated head and neck cancers in France using population‐based cancer registries data: 1980–2012

“…A study reported an overall HPV prevalence of 46.5% (PCR) in oropharyngeal cancer (53.7%‐tonsil, 30.2%‐base of tongue) for the period 2000–2009 . A second and a third studies reported an HPV prevalence in oropharyngeal cancer of 50% (detection of p16 expression using immunohistochemistry)−65% (PCR) for the period 2007–2009 and of 30.4% for the period 2007–2010 . By contrast, in Sweden, the prevalence of HPV (PCR) in tonsil cancer was evaluated at 93% in 2006–2007 and at 84% in 2004–2007 in base of the tongue cancer.…”

“…Incidence is steadily decreasing in men and increasing in women . Studies have reported an overall HPV prevalence in oropharyngeal cancer (PCR) comprised between 30.4% and 65.4% . However, the potential impact of HPV infection on incidence trends is unknown.…”

“…14,15 Studies have reported an overall HPV prevalence in oropharyngeal cancer (PCR) comprised between 30.4% and 65.4%. 13,16,17 However, the potential impact of HPV infection on incidence trends is unknown. The aim of this study is to explore changes in HNC incidence in France, potentially in relation with infection by HPV: we assessed differences in incidence between possible HPV-related and HPV-unrelated HNC for the period 1980 to 2012.…”

[18F]-FDG PET-CT prediction of response to induction chemotherapy in head and neck squamous cell carcinoma: Preliminary findings

“…In France, however, HPV infection is found in only 11.5-26% of cases of HNSCC [14]. ERCC1 gene expression and DPD (dihydropyrimidin dehydrogenase) cyclin D1 mutations [15,16] also offer interesting possibilities.…”

Intérêt prédictif de la TEP-TDM au [18F]-FDG pour la réponse à la chimiothérapie d’induction dans le traitement des carcinomes épidermoïdes des voies aéro-digestives supérieures : résultats préliminaires

“…Afin d'obtenir une valeur prédictive de l'efficacité de la chimiothérapie d'induction et d'en diminuer ses toxicités, des études biomoléculaires et génétiques sont en cours : l'infection à papillomavirus humain (HPV) et plus particulièrement la présence de p53 et des ARNm des oncoprotéines E6 et E7 dans les carcinomes épidermoïdes de l'oropharynx apparaissent comme un facteur de bon pronostic, et de bonne réponse à la radiochimiothérapie. Toutefois, cette infection à HPV n'est retrouvée en France que dans 11,5 à 26 % des carcinomes épidermoïdes des VADS [14]. L'expression du gène ERCC1, la recherche de la mutation de la dihydropyrimidine déhydrogénase (DPD) ou de la cycline D1 [15,16] sont également des pistes intéressantes.…”